TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05096845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant SARS-CoV-2 fusion protein vaccine (V-01)
Description: Appearance: creamy white suspension Dosage form: Suspension for injection Strength: 10 μg (0.5mL) /vial Vaccination route: intramuscular injection into the lateral deltoid of the upper arm Vaccination dosage: 10 μg Immunization schedule: two doses, one each on Day 0 and 21 (+7 days), respectively.~Storage condition: store at 2\~8°C protected from light Expiry date: 24 months after production date

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)
Description: The dosage, appearance, administration method, and other aspects are consistent with that of investigational vaccine, except that no vaccine antigen is contained.
Study: NCT04796350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AGN1 LOEP treatment
Description: the implantation site is injected with the AGN1 implant material
Study: NCT05188651

Intervention type: BEHAVIORAL
Intervention: face masks
Description: wearing face masks

Intervention type: BEHAVIORAL
Intervention: face masks
Description: wearing face masks
Study: NCT05224674

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Description: The ESWT device is product of Elettronica Pagani, Italy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Description: The ESWT device is product of Elettronica Pagani, Italy.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Description: The ESWT device is product of Elettronica Pagani, Italy.
Study: NCT05042947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double-loop clips
Description: a new ligation method using the double-loop clips (D-L clips) technique

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium Clip
Description: the Titanium Clip
Study: NCT05979766

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual lymphatic drainage versus marian clark drainage
Description: Manual lymphatic drainage versus marian clark drainage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual lymphatic drainage versus marian clark drainage
Description: Manual lymphatic drainage versus marian clark drainage
Study: NCT05942664

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sleep
Description: Sleep will be restricted to 60% normal sleep duration

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep
Description: Sleep will be restricted to 60% normal sleep duration
Study: NCT05577182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA32459-101
Description: solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA32459-101
Description: solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCA32459-101
Description: solution for infusion
Study: NCT06104098

Intervention type: DEVICE
Group type: OTHER
Intervention: D005 vaginal mousse
Description: D005 Vaginal Mousse is class IIa medical device for treatment of Bacterial Vaginosis.
Study: NCT05874622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 tablets
Description: VC005 groups repeat administration for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 tablets
Description: VC005 groups repeat administration for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 tablets
Description: VC005 groups repeat administration for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 Tablets Placebo
Description: VC005 placebo groups repeat administration for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 Tablets Placebo
Description: VC005 placebo groups repeat administration for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 Tablets Placebo
Description: VC005 placebo groups repeat administration for 4 weeks
Study: NCT06006624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel 30 mL
Description: 30 mL Liposomal bupivacaine (Exparel) evenly distributed and administered in adductor canal block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel 30 mL
Description: 30 mL Liposomal bupivacaine (Exparel) evenly distributed and administered in adductor canal block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% bupivacaine
Description: 5 cc's of 0.5% bupivacaine evenly distributed and administered in adductor canal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% bupivacaine
Description: 5 cc's of 0.5% bupivacaine evenly distributed and administered in adductor canal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 10 mg preservative free Dexamethasone evenly distributed and administered in adductor canal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iPACK block
Description: iPACK (Infiltration between the Popliteal artery and Capsule of the Knee) block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iPACK block
Description: iPACK (Infiltration between the Popliteal artery and Capsule of the Knee) block
Study: NCT04850014

Intervention type: OTHER
Intervention: Anthropomorphism
Description: Height, weight, body surface area, body mass index, exact age (date of birth or age in days, months and years), falling which year of birth gender

Intervention type: OTHER
Intervention: Anthropomorphism
Description: Height, weight, body surface area, body mass index, exact age (date of birth or age in days, months and years), falling which year of birth gender

Intervention type: OTHER
Intervention: Relevant clinical datas
Description: Medical history Concomitant medication Paracetamol intake : dosage, delay, context, route of intake Alcohol intake Smoking status (including active and passive exposition or no exposition) Curative treatment / Antidote / purifying treatment received and time of introduction Clinical signs, Acetaminophen concentration in plasma with associated accurate time of sampling (date, hour and time following acetaminophen intake Liver and kindney function assessment by measure measuring plasma concentration of: AST, ALT, Factor V, Prothrombin, APTT, INR, albuminemia, bilirubin, phosphorus, pH, creatitine. And GFR estimation.~Imaging.

Intervention type: OTHER
Intervention: Relevant clinical datas
Description: Medical history Concomitant medication Paracetamol intake : dosage, delay, context, route of intake Alcohol intake Smoking status (including active and passive exposition or no exposition) Curative treatment / Antidote / purifying treatment received and time of introduction Clinical signs, Acetaminophen concentration in plasma with associated accurate time of sampling (date, hour and time following acetaminophen intake Liver and kindney function assessment by measure measuring plasma concentration of: AST, ALT, Factor V, Prothrombin, APTT, INR, albuminemia, bilirubin, phosphorus, pH, creatitine. And GFR estimation.~Imaging.
Study: NCT05114616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NextSense EEG-enabled earbuds
Description: Each NextSense EEGBud device comes with a universal-fit and/or custom-fit earmold with biometric sensors to detect the EEG, motion (via tri-axial accelerometers), and heart rate. The custom mold is created employing a 3D printer following capture of the geometry unique to each patients' ears with a ring laser scanner to an accuracy of within 0.1 mm. This design process allows for a custom fit and therefore both comfort and complete, consistent contact with the inner surface of the ear canal, providing high quality capture of signals reflecting brain activity, and head, and eye movements. In addition to the custom fit earmold, universal fit earmolds are available as well. The universal fit earmolds were designed also to allow for comfort and consisten contact with the inner surface of the ear canal to provide high quality signal capture of brain activity, and head and eye movements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ellcie Healthy Glasses
Description: Ellcie Healthy glasses frames are embedded with multi-modal sensors for measuring eye movements, head movement, and ECG.
Study: NCT05669820

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Salovum
Description: Salovum is an eggyolkpowder derived from hens fed with SPC (specially processed cereals) and contains increased amounts of the endogenous protein antisecretory factor.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo egg yolk powder
Description: Egg yolk powder derived from hen fed with normal feed.
Study: NCT04736745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Powder for solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Powder for solution for injection
Study: NCT04255303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated clinical prediction rule (iCPR) system (iCPR)
Description: The iCPR tool consists of an electronic calculator that can be used to determine whether the patient is at low, intermediate or high risk for having the diagnosis and a bundled order set (called a Smartset). The iCPR tool will be made available directly within the Electronic Health Record (EHR) for Registered Nurses (RNs) who are seeing patients fall into the study categories. The iCPR tool through the use of order sets will guide the RN in the patient's care. The order set for patients at low risk for these diseases will recommend supportive care including over the counter cold remedies and pain relievers. The order set for patients at intermediate or high risk of these disease will recommend diagnostic tests (rapid strep antigen or CXR) to help determine if they have the disease. Based on the results of the diagnostic tests new order sets will recommend antibiotics or supportive care
Study: NCT05397639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masupirdine 50 mg
Description: Tablet, Once Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masupirdine 100 mg
Description: Tablet, Once Daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Tablet, Once Daily
Study: NCT04706156

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Receiving coronavirus disease (COVID-19) vaccine e.g. Pfizer-BioNTech, Moderna, Oxford/AstraZeneca, or Sinovac COVID-19 Vaccine

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Receiving coronavirus disease (COVID-19) vaccine e.g. Pfizer-BioNTech, Moderna, Oxford/AstraZeneca, or Sinovac COVID-19 Vaccine

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Receiving coronavirus disease (COVID-19) vaccine e.g. Pfizer-BioNTech, Moderna, Oxford/AstraZeneca, or Sinovac COVID-19 Vaccine

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Receiving coronavirus disease (COVID-19) vaccine e.g. Pfizer-BioNTech, Moderna, Oxford/AstraZeneca, or Sinovac COVID-19 Vaccine
Study: NCT04654078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C004 with water
Description: One time dose of IN-C004 taken with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C004 with water
Description: One time dose of IN-C004 taken with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C004 with water
Description: One time dose of IN-C004 taken with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C004 with water
Description: One time dose of IN-C004 taken with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C004 with water
Description: One time dose of IN-C004 taken with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C004 with water
Description: One time dose of IN-C004 taken with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C004 without water
Description: One time dose of IN-C004 taken without water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C004 without water
Description: One time dose of IN-C004 taken without water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C004 without water
Description: One time dose of IN-C004 taken without water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C004 without water
Description: One time dose of IN-C004 taken without water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C004 without water
Description: One time dose of IN-C004 taken without water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C004 without water
Description: One time dose of IN-C004 taken without water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-CAB tab. with water
Description: One time dose of K-CAB tab. taken with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-CAB tab. with water
Description: One time dose of K-CAB tab. taken with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-CAB tab. with water
Description: One time dose of K-CAB tab. taken with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-CAB tab. with water
Description: One time dose of K-CAB tab. taken with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-CAB tab. with water
Description: One time dose of K-CAB tab. taken with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-CAB tab. with water
Description: One time dose of K-CAB tab. taken with water
Study: NCT05050656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine 60mg
Description: Duloxetine is a selective SNRI prescribed in depression, anxiety, and chronic pain like diabetic neuropathy and fibromyalgia, it acts through central and peripheral pain modulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets identical to duloxetine tablets
Study: NCT05685537

Intervention type: DRUG
Intervention: Levosimendan
Description: Initiation of levosimendan 48 hours before surgery
Study: NCT06419062

Intervention type: DEVICE
Intervention: Frontier X2
Description: Frontier X2 device will be used to measuring for physiological changes (breathing rate, heart rate, ECG, and heart rate variabilities) in people with COPD.
Study: NCT05141721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT-C901
Description: A patient-specific neoantigen cancer vaccine administered via intramuscular (IM) injection as prime and single boost at a dose of 1x10\^12 viral particles 2 times over the course of the first year.
Study: NCT05141721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT-R902
Description: A patient-specific neoantigen cancer vaccine boost, administered via IM injection at a dose of 30ug 4 times over the course of the first year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered via intravenous (IV) infusion at a dose of 1680 mg once every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered via subcutaneous (SC) injection at a dose of 30 mg with the first dose of GRT-C901 and GRT-R902.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoropyrimidine plus leucovorin
Description: Fluoropyrimidine (infusional 5-FU or capecitabine) and leucovorin administered as maintenance therapy per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine plus leucovorin
Description: Fluoropyrimidine (infusional 5-FU or capecitabine) and leucovorin administered as maintenance therapy per standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab administered as maintenance therapy per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab administered as maintenance therapy per standard of care.
Study: NCT05393141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet and biopsychosocial exercise intervention
Description: dietary intervention: biopsychosocial exercise intervention:

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet and biopsychosocial exercise intervention
Description: dietary intervention: biopsychosocial exercise intervention:
Study: NCT05603559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.1 GBq (30 mCi) of 177Lu-P17-087
Description: All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-087 then monitored at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours and 168 hours post-injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.1 GBq (30 mCi) of 177Lu-P17-088
Description: All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-088 then monitored at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours and 168 hours post-injection.
Study: NCT04733651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hospital standard of care for COVID-19
Description: Standard care for COVID-19 as per the hospital guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hospital standard of care for COVID-19
Description: Standard care for COVID-19 as per the hospital guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoquercetin
Description: Daily 1000 mg Isoquercetin as 4 capsules
Study: NCT06218238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Powered prosthetic knee joint
Description: Subjects will be fitted and trained on the Ossur Power Knee. An accommodation of 1 month will be provided prior to evaluation with the knee joint.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional prosthetic knee joint
Description: Subjects will be fitted and trained on the Ossur Rheo XC Knee. An accommodation of 1 month will be provided prior to evaluation with the knee joint.
Study: NCT05322174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baby Sleep
Description: See arm description
Study: NCT05216471

Intervention type: RADIATION
Intervention: chest X-ray
Description: Chest Xray : postero-anterior view ,digital high resolution X-ray or ,full inspiratory

Intervention type: RADIATION
Intervention: chest X-ray
Description: Chest Xray : postero-anterior view ,digital high resolution X-ray or ,full inspiratory

Intervention type: RADIATION
Intervention: chest X-ray
Description: Chest Xray : postero-anterior view ,digital high resolution X-ray or ,full inspiratory
Study: NCT05433597

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-fu
Description: 5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fu
Description: 5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin: 80mg/m2, used on the 1st and 28th day of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin: 80mg/m2, used on the 1st and 28th day of each cycle.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy: Radiotherapy was initiated on day 15 of the first cycle of chemotherapy . GTV: 6810cGy (227 cGy/30f) Or 6996 cGy (212 cGy/ 33F); CTV: 5400-6000 cGy (180-200 cGy/f); Radiotherapy once a day, 5 times a week, a total of 30-33 times, a total of about 6 weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy: Radiotherapy was initiated on day 15 of the first cycle of chemotherapy . GTV: 6810cGy (227 cGy/30f) Or 6996 cGy (212 cGy/ 33F); CTV: 5400-6000 cGy (180-200 cGy/f); Radiotherapy once a day, 5 times a week, a total of 30-33 times, a total of about 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNF
Description: TNF (recombinant human tumor necrosis factor for injection) : 1 million IU (BSA\<2.0m2) or 1.5 million IU (BSA≥2.0m2), dissolved in normal saline 1-2mL, intramuscular, QD, 30 days in the first and third months, once a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 1-2ml normal saline, intramuscular injection, QD, once a day, 30 days in the first and third months.
Study: NCT04747028

Intervention type: DIAGNOSTIC_TEST
Intervention: Dmf score
Description: A chart to calculate the caries index

Intervention type: DIAGNOSTIC_TEST
Intervention: Dmf score
Description: A chart to calculate the caries index
Study: NCT05800275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib Oral Tablet
Description: 300 mg, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine tablets
Description: 1000 mg/m², twice daily on days 1-14 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Injection
Description: Intrathecal by lumbar puncture or Ommaya Reservoir, 150 mg weekly
Study: NCT04946331

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical impedance tomography system
Description: Which can use the applied current and measurement voltage through the body surface electrode group, and use the reconstruction algorithm to construct an image imaging system that exceeds the cross-sectional, which can provide images of the internal physiological changes of the chest contour, in order to quantify the changes in lung function caused by rib fractures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical impedance tomography system
Description: Which can use the applied current and measurement voltage through the body surface electrode group, and use the reconstruction algorithm to construct an image imaging system that exceeds the cross-sectional, which can provide images of the internal physiological changes of the chest contour, in order to quantify the changes in lung function caused by rib fractures.
Study: NCT05322174

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baby Care
Description: See arm description
Study: NCT06199453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium (177Lu) vipivotide tetraxetan
Description: 6 cycles of lutetium (177Lu) vipivotide-tetraxetan with an activity of 200 mCi (7.4 GBq) at intervals of 6 weeks
Study: NCT06584019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Range Of Motion applied group
Description: Range Of Motion was applied once a day for approximately 20 minutes for 5 days.
Study: NCT04924153

Intervention type: OTHER
Intervention: No Intervention
Description: Administered as specified in the treatment arm.

Intervention type: OTHER
Intervention: No Intervention
Description: Administered as specified in the treatment arm.

Intervention type: OTHER
Intervention: No Intervention
Description: Administered as specified in the treatment arm.

Intervention type: OTHER
Intervention: No Intervention
Description: Administered as specified in the treatment arm.